Eli Lilly and Company is looking to boost supplies of its obesity drug Zepbound (tirzepatide) by offering single-dose vials of the drug through its self-pay channel, at a cost that it described as being at least 50% less than other incretin medicines for obesity.
Lilly To Offer Zepbound Single-Dose Vials To Self-Pay Consumers
The company is offering Zepbound in single-dose 2.5mg and 5mg vials, both to expand supply and access, especially for patients without coverage for the obesity drug.
More from Strategy
• By
With the FDA asking for another Phase III trial, the short bowel syndrome drug apraglutide could be years away from market, while the Linzess patent expiry and near-term debt loom.
• By
The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.
• By
Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.
• By
Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.
More from Business
• By
The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.
• By
In this week's episode: Trump’s tariff rollercoaster; regulatory, economic uncertainties hang over Q1 earnings; IPOs rise in Q1 but may slow; Chinese deal-making matures; and AstraZeneca talks about Chinese innovation.
• By
Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.